Elaia

?? Get to know HEPHAISTOS-Pharma’s CEO, Frederic CAROFF! HEPHAISTOS-Pharma targets the innate immune system to address the key issues of tumor resistance today, especially patients who are facing hard-to-treat and solid tumors such as sarcoma or rectal cancer. Without any current therapeutic solutions on the market today, Hephaistos offers a solution that can be used both in mono- and combined therapies. Learn more here ?? https://lnkd.in/e73dcCsk

??Meet Elaia's newest Deep Tech Seed Analyst: Elfwa Ljungdahl! Born in Stockholm and a graduate of Chalmers University of Technology, Elfwa brings a mix of international experience to the Elaia team, having spent time in cities including Paris, Berlin, and Brussels. Most recently, she was an analyst at Neudi & C:o AB, a Stockholm based family office, focusing on portfolio support, investment opportunities, and deal analysis. ?? Elfwa is particularly committed to transformative technologies - especially in the fields of life sciences, climate tech, and AI so don’t hesitate to reach out to her if you’re building in these spaces!

?? Ever wondered how Elaia Managing Partner, Anne-Sophie CARRESE, got her start in deep tech? In conversation with Gilles Fontaine and Guillaume Payan on the latest episode of the Challenges #DeepTechs podcast, Anne-Sophie shares how her roots in aeronautical engineering laid the groundwork for building out the deep tech practice at Elaia nearly ten years ago. Tune in here ???https://lnkd.in/eWeaaGg6

???? Will you be in the Bay Area for NVIDIA #GTC2025 next week? Don't miss the opportunity to connect with the Elaia team on the ground, including Alexis Frentz, Investment Director, and Clément Vanden Driessche, Partner, at one of the biggest events in AI. Want to see Elaia onstage? Catch Clément in the VC reverse pitch session on March 19th from 2-3pm!

???GLEAMER acquires PIXYL and Caerus Medical! Why does this matter? Because now, Gleamer is the only provider with proprietary AI-driven solutions across all major imaging types—X-ray, Mammography, CT, and MRI. This isn’t just about growing bigger—it’s about giving radiologists the absolute best tools to work faster, spot issues more accurately, and make patient care smoother and swifter with next-generation imaging solutions. Congratulations Christian Allouche, Noé Poyet and the Gleamer team!

?? Elaia is looking for our next three interns! We are offering the opportunity to join as: ???A VC Analyst intern for our Digital Venture fund, which invests from Seed to Series B in unicorns such as Mirakl and Criteo and rising stars like Vibe.co and Mitiga Solutions ???A VC Analyst intern for our Deep Tech Seed fund, which invests from pre-seed to seed tech-intensive startups like Sonio, AQEMIA and Alice & Bob ???A Compliance Intern to work closely with our head of Compliance, working on audit, risk management and AML/KYC processes At Elaia, we????technology & innovation and we pursue performance with passion & strong values: ???Team spirit is core to what we do ???We encourage each other to strive for personal & collective excellence ???We practice transparency towards both our team and our entrepreneurs We care about creating an environment where everyone is inspired to thrive & develop together. Some of the values that we encourage in the team early on are proactivity, autonomy and responsibility. If these values sound like you and you thrive in a technical, analytical, and fast-paced culture, we’d be glad to have you onboard! Check out the comments for the links to apply!

?? Congratulations to hema.to GmbH on securing its latest €3.6M funding round. hema.to’s AI-driven tech wants to transform blood data analysis, by speeding up diagnostics and enhancing accuracy in detecting serious conditions like leukemia and lymphoma. By automating the cytometry process, hema.to reduces analysis time dramatically from 20 minutes to just 1 minute, significantly reducing human error and false negatives. By accelerating an early and precise diagnosis, hema.to offers a way for phyisicians to save time and lives. Led by LUMO Labs and Bayern Kapital, this funding round will be used to refine product-market-fit in hema.to’s first segment of blood cancer diagnostics, including additional European certification, and for clinical studies, expansion into diagnosis of broader immune disorders, and scaling commercial deployment. Congrats to Karsten Miermans and the hema.to team!

???We’re kicking off March by announcing several well-deserved promotions in the Elaia team! These promotions reflect each individual’s hard work, team spirit and dedication to going above and beyond during their time at Elaia. As Elaia?continues to?grow, we are committed to recognizing the exceptional talents in our team. ?? Arturo Ancira García is named Associate in our Deep Tech Seed Team ?? Léa Billaud is named Associate in our Investor Relations Team ?? Anya Brochier is named Senior Associate in our Marketing & Communications Team ?? Maxime Lhoustau is named Investment Manager in our Deep Tech Seed team ?? Arthur Liabastre is named Senior Finance Officer in our Finance team ?? Julien Macquet is named Investment Manager in our Deep Tech Seed team ?? Valentin Sauvaire is named Associate in our Digital Venture team Please join us in sharing our congratulations!

?? Attention deep tech founders! Heading to Hello Tomorrow in March? We're teaming up with Atlantic Labs and IQ Capital to host an exclusive lunch on March 13th celebrating the best of deep tech innovation just steps away from the conference. Spots are limited, so register soon! Check the comments for the RSVP link.

Zymvol Biomodeling raises €3M to democratize the use of improved, sustainable enzymes across industries! We’re excited to continue our support of ZYMVOL as co-lead of this round alongside Faber and übermorgen Ventures as ZYMVOL looks to enhance its experimental lab in the Barcelons Science Park, expand its proprietary tech, grow its sales & marketing team and bring its first custom-made enzyme kits to the market. Since its founding in 2017, ZYMVOL has established itself as a leader in computational enzyme discovery and design.?Based between Barcelona and Boston, it partners with R&D teams from some of the world’s largest firms to transform their production processes—boosting innovation and reducing environmental impact—through tailored enzymatic solutions. “Over the past few years, Zymvol has revolutionised the way enzymes are discovered and engineered. Zymvol now outperforms alternative solutions across all key factors, including speed of development, specificity and efficiency. We are pleased to continue supporting the company as it expands its portfolio of enzymes and scales operations internationally.” said Sébastien Lefebvre, Partner at Elaia. Congratulations to Maria Fátima Lucas and the ZYMVOL team!